ZEALAND PHARMA A/S (22Z.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:22Z • DK0060257814

55.74 EUR
+1.24 (+2.28%)
Last: Feb 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Overall 22Z gets a fundamental rating of 6 out of 10. We evaluated 22Z against 81 industry peers in the Biotechnology industry. While 22Z has a great health rating, its profitability is only average at the moment. 22Z is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make 22Z a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year 22Z was profitable.
  • In the past year 22Z had a positive cash flow from operations.
  • In the past 5 years 22Z always reported negative net income.
  • 22Z had a negative operating cash flow in each of the past 5 years.
22Z.DE Yearly Net Income VS EBIT VS OCF VS FCF22Z.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 38.95%, 22Z belongs to the top of the industry, outperforming 97.53% of the companies in the same industry.
  • The Return On Equity of 22Z (43.15%) is better than 98.77% of its industry peers.
  • 22Z has a Return On Invested Capital of 32.76%. This is amongst the best in the industry. 22Z outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 38.95%
ROE 43.15%
ROIC 32.76%
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
22Z.DE Yearly ROA, ROE, ROIC22Z.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • With an excellent Profit Margin value of 71.47%, 22Z belongs to the best of the industry, outperforming 97.53% of the companies in the same industry.
  • 22Z has a better Operating Margin (79.38%) than 98.77% of its industry peers.
  • Looking at the Gross Margin, with a value of 99.99%, 22Z belongs to the top of the industry, outperforming 97.53% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 22Z has declined.
Industry RankSector Rank
OM 79.38%
PM (TTM) 71.47%
GM 99.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
22Z.DE Yearly Profit, Operating, Gross Margins22Z.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • 22Z has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for 22Z has been increased compared to 1 year ago.
  • The number of shares outstanding for 22Z has been increased compared to 5 years ago.
  • Compared to 1 year ago, 22Z has an improved debt to assets ratio.
22Z.DE Yearly Shares Outstanding22Z.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
22Z.DE Yearly Total Debt VS Total Assets22Z.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 10.15 indicates that 22Z is not in any danger for bankruptcy at the moment.
  • 22Z has a Altman-Z score of 10.15. This is amongst the best in the industry. 22Z outperforms 87.65% of its industry peers.
  • The Debt to FCF ratio of 22Z is 0.06, which is an excellent value as it means it would take 22Z, only 0.06 years of fcf income to pay off all of its debts.
  • 22Z has a Debt to FCF ratio of 0.06. This is amongst the best in the industry. 22Z outperforms 96.30% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that 22Z is not too dependend on debt financing.
  • 22Z has a Debt to Equity ratio of 0.03. This is in the better half of the industry: 22Z outperforms 71.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.06
Altman-Z 10.15
ROIC/WACC4.5
WACC7.28%
22Z.DE Yearly LT Debt VS Equity VS FCF22Z.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

  • 22Z has a Current Ratio of 14.10. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of 22Z (14.10) is better than 96.30% of its industry peers.
  • 22Z has a Quick Ratio of 14.10. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 14.10, 22Z belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.1
Quick Ratio 14.1
22Z.DE Yearly Current Assets VS Current Liabilites22Z.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • 22Z shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 661.53%, which is quite impressive.
  • The Revenue has grown by 11809.72% in the past year. This is a very strong growth!
  • The Revenue has been growing by 8.69% on average over the past years. This is quite good.
EPS 1Y (TTM)661.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.52%
Revenue 1Y (TTM)11809.72%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%1022.74%

3.2 Future

  • 22Z is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.30% yearly.
  • The Revenue is expected to grow by 87.70% on average over the next years. This is a very strong growth
EPS Next Y670.67%
EPS Next 2Y71.65%
EPS Next 3Y3.17%
EPS Next 5Y5.3%
Revenue Next Year11460.5%
Revenue Next 2Y697.65%
Revenue Next 3Y250.19%
Revenue Next 5Y87.7%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
22Z.DE Yearly Revenue VS Estimates22Z.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
22Z.DE Yearly EPS VS Estimates22Z.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 -20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • 22Z is valuated cheaply with a Price/Earnings ratio of 4.48.
  • 97.53% of the companies in the same industry are more expensive than 22Z, based on the Price/Earnings ratio.
  • 22Z is valuated cheaply when we compare the Price/Earnings ratio to 28.06, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 27.04, 22Z can be considered very expensive at the moment.
  • 22Z's Price/Forward Earnings ratio is rather cheap when compared to the industry. 22Z is cheaper than 80.25% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.86. 22Z is around the same levels.
Industry RankSector Rank
PE 4.48
Fwd PE 27.04
22Z.DE Price Earnings VS Forward Price Earnings22Z.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 22Z indicates a rather cheap valuation: 22Z is cheaper than 97.53% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 2.6
EV/EBITDA -0.93
22Z.DE Per share data22Z.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y71.65%
EPS Next 3Y3.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 22Z!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZEALAND PHARMA A/S

FRA:22Z (2/9/2026, 7:00:00 PM)

55.74

+1.24 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)02-19
Inst Owners47.48%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap2.57B
Revenue(TTM)9.16B
Net Income(TTM)6.54B
Analysts81.67
Price Target96.27 (72.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.92%
Min EPS beat(2)-5.54%
Max EPS beat(2)31.39%
EPS beat(4)2
Avg EPS beat(4)-143.51%
Min EPS beat(4)-623.11%
Max EPS beat(4)31.39%
EPS beat(8)3
Avg EPS beat(8)-73.88%
EPS beat(12)5
Avg EPS beat(12)-38.79%
EPS beat(16)7
Avg EPS beat(16)-27.86%
Revenue beat(2)1
Avg Revenue beat(2)21.02%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)45.58%
Revenue beat(4)1
Avg Revenue beat(4)-24.03%
Min Revenue beat(4)-74.61%
Max Revenue beat(4)45.58%
Revenue beat(8)4
Avg Revenue beat(8)20.68%
Revenue beat(12)7
Avg Revenue beat(12)58.52%
Revenue beat(16)7
Avg Revenue beat(16)31.76%
PT rev (1m)-2.81%
PT rev (3m)-10.67%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)-35.21%
EPS NY rev (1m)0.23%
EPS NY rev (3m)3.26%
Revenue NQ rev (1m)-9.12%
Revenue NQ rev (3m)-18.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.32%
Valuation
Industry RankSector Rank
PE 4.48
Fwd PE 27.04
P/S 2.1
P/FCF 2.6
P/OCF 2.6
P/B 1.27
P/tB 1.27
EV/EBITDA -0.93
EPS(TTM)12.45
EY22.34%
EPS(NY)2.06
Fwd EY3.7%
FCF(TTM)21.4
FCFY38.39%
OCF(TTM)21.47
OCFY38.51%
SpS26.58
BVpS44.02
TBVpS43.98
PEG (NY)0.01
PEG (5Y)N/A
Graham Number111.04
Profitability
Industry RankSector Rank
ROA 38.95%
ROE 43.15%
ROCE 46.53%
ROIC 32.76%
ROICexc N/A
ROICexgc N/A
OM 79.38%
PM (TTM) 71.47%
GM 99.99%
FCFM 80.53%
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
F-Score8
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.06
Debt/EBITDA 0.05
Cap/Depr 86.21%
Cap/Sales 0.24%
Interest Coverage 432.5
Cash Conversion 101.39%
Profit Quality 112.67%
Current Ratio 14.1
Quick Ratio 14.1
Altman-Z 10.15
F-Score8
WACC7.28%
ROIC/WACC4.5
Cap/Depr(3y)51.82%
Cap/Depr(5y)53.82%
Cap/Sales(3y)13.05%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)661.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.52%
EPS Next Y670.67%
EPS Next 2Y71.65%
EPS Next 3Y3.17%
EPS Next 5Y5.3%
Revenue 1Y (TTM)11809.72%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%1022.74%
Revenue Next Year11460.5%
Revenue Next 2Y697.65%
Revenue Next 3Y250.19%
Revenue Next 5Y87.7%
EBIT growth 1Y751.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year737.44%
EBIT Next 3Y-7.65%
EBIT Next 5Y17.72%
FCF growth 1Y1048.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1076.19%
OCF growth 3YN/A
OCF growth 5YN/A

ZEALAND PHARMA A/S / 22Z.DE FAQ

What is the ChartMill fundamental rating of ZEALAND PHARMA A/S (22Z.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE.


What is the valuation status for 22Z stock?

ChartMill assigns a valuation rating of 6 / 10 to ZEALAND PHARMA A/S (22Z.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for ZEALAND PHARMA A/S?

ZEALAND PHARMA A/S (22Z.DE) has a profitability rating of 5 / 10.


How financially healthy is ZEALAND PHARMA A/S?

The financial health rating of ZEALAND PHARMA A/S (22Z.DE) is 9 / 10.


Can you provide the expected EPS growth for 22Z stock?

The Earnings per Share (EPS) of ZEALAND PHARMA A/S (22Z.DE) is expected to grow by 670.67% in the next year.